Collegium Pharma (COLL) Tops Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Collegium Reports Net Income of $8.1 Million in the Second Quarter of 2020
August 5, 2020 4:02 PM EDT Non-GAAP Net Income of $33.2 Million in the Second Quarter of 2020
Generated $43.9 Million in Cash from Operating Activities in the Second Quarter of 2020
Xtampza ® ER Net Revenue Increased 29% over the Prior Year Period
Conference Call Scheduled for Today at 4:30 p.m. ET
STOUGHTON, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Â Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today reported... More
